Efforts to induce anti-tumor immunity have so far proven disappointing. Now, Tyler Curiel, Weiping Zou (Tulane University, New Orleans, LA), and colleagues suggest that greater success may come if clinicians first disable regulatory T (T~reg~) cells. These cells, say the group, are recruited by human tumors to damp down any immune response against tumor cells.

FigureRegulatory T cells (green) contact other T cells (red) to prevent effective tumor immunity.Zou/Macmillan

T~reg~ cells have been studied primarily for their ability to turn off immune responses during organ transplantation or autoimmune disease. Preliminary results in mice suggested that depletion of T~reg~ cells might improve tumor prognosis, although these experiments may have depleted other cell types.

Now, Zou\'s team finds that human malignant ovarian cancers contain substantial numbers of T~reg~ cells, with more T~reg~ cells present at later tumor stages. The patients also have fewer than normal T~reg~ cells in their lymph nodes---the normal home of the cells. In mice containing human tumor cells the T~reg~ accumulation in tumors is dependent on the chemokine CCL22, which is produced at high levels by macrophages in the tumors.

Transfer of T~reg~ cells to mice blocked the protective effects of tumor-specific effector T cells. And human patients with more T~reg~ cells had a poorer prognosis, even after controlling for tumor stage.

T~reg~ cells probably function primarily in switching off an immune response so that it does not get out of control. Tumors appear to have coopted this mechanism to create a privileged environment for themselves. Zou is now pursuing a clinical trial to disable T~reg~ cells. "You have to get rid of these suppressive mechanisms," he says, "and only then can you push the tumor-specific immunity." ▪
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